Nutra Pharma Announces Contracts for Nyloxin Television Commercials
10 June 2014 - 10:00PM
Marketwired
Nutra Pharma Announces Contracts for Nyloxin Television Commercials
Nutra Pharma Is Announcing That MyNyloxin.com Has Contracted for
the Rollout of Television Commercials for Their Marketing Campaign
of the Company's Over-the-Counter (OTC) Pain Reliever,
Nyloxin(R)
CORAL SPRINGS, FL--(Marketwired - Jun 10, 2014) - Nutra Pharma
Corp. (OTC: NPHC), a biotechnology company that is developing
treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple
Sclerosis (MS), is announcing that MyNyloxin.com, a new company
that has the exclusive rights to market and distribute Nutra
Pharma's over-the-counter (OTC) pain reliever, Nyloxin®, has signed
contracts to begin airing television commercials beginning June
23rd. The advertisements focus on the benefits of Nyloxin®. The
first contract includes over 30,000 spots to run throughout the
Southeast Region from Comcast and AT&T U-Verse Cable providers.
The ads are scheduled to run on the following channels: GOLF, LMN,
CNBC, FOXN, MSNBC, NBCS, ESPN, ESPN2, TNT, FOXS, TWC, CNN, HALL,
HGTV, TLC, HLN and LIFE.
"MyNyloxin has been working diligently with our creative team to
get these commercials completed," stated Dalton Johnson, CEO of
MyNyloxin.com. "The initial rollout is throughout the South Florida
market with eventual expansion into the Northeast and California
markets in the coming months," he continued. "We believe that these
advertisements will capture the imagination of potential customers
that need access to a superior pain relief product and should help
grow sales in the short term," he concluded.
Nyloxin® is an over-the-counter (OTC) pain reliever clinically
proven to treat moderate to severe (Stage 2) chronic
pain. Nyloxin® is currently available in the United States as
an oral spray for treating back pain, neck aches, headaches, joint
pain, migraines, and neuralgia, and as a topical gel for treating
joint pain, neck pain, arthritis pain, and pain from repetitive
stress. In addition to its everyday strength formulation, Nyloxin®
is also offered in an extra strength formula for more advanced,
Stage 3, chronic pain.
"MyNyloxin Distributors have been consistently increasing the
public awareness of Nyloxin," said Rik J Deitsch, Chairman and CEO
of Nutra Pharma Corporation. "They will be targeting these
commercials in areas that are expected to provide the widest market
for our pain relief products, with the eventual rollout to the
national stage over the next several months," he concluded.
The commercials can be viewed online at:
http://tinyurl.com/NyloxinAds
About Nutra Pharma Corp. Nutra Pharma Corporation operates as a
biotechnology company specializing in the acquisition, licensing,
and commercialization of pharmaceutical products and technologies
for the management of neurological disorders, cancer, autoimmune,
and infectious diseases, including Multiple Sclerosis (MS), Human
Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain.
Additionally, the Company markets several drug products for sale
for the treatment of pain under the brands Cobroxin® and Nyloxin®.
For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or http://www.Nyloxin.com.
SEC Disclaimer This press release contains forward-looking
statements. The words or phrases "would be," "will allow," "intends
to," "will likely result," "are expected to," "will continue," "is
anticipated," "estimate," "project," or similar expressions are
intended to identify "forward-looking statements." Actual results
could differ materially from those projected in Nutra Pharma's
("the Company") business plan. The contract to run Nyloxin
commercials should not be construed as an indication in any way
whatsoever of the future value of the Company's common stock or its
financial value. The Company's filings may be accessed at the SEC's
Edgar system at www.sec.gov. Statements made herein are as of
the date of this press release and should not be relied upon as of
any subsequent date. The Company cautions readers not to place
reliance on such statements. Unless otherwise required by
applicable law, we do not undertake, and we specifically disclaim
any obligation, to update any forward-looking statements to reflect
occurrences, developments, unanticipated events or circumstances
after the date of such statement.
Contact: Nutra Pharma Corp. Nina Goldstein 877-895-5647
IR@nutrapharma.com
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Dec 2024 to Jan 2025
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Jan 2024 to Jan 2025
